

Clinical Perspectives on the Evolution of NSCLC Treatment With I-O and ROS1 TKIs



Saturday, 21 October 2023 | 13:00 – 14:20 CEST

Salamanca Auditorium – Hall 3, IFEMA MADRID, Madrid, Spain

Available On Demand Until Wednesday, 8 November 2023



Meeting Chair
Jürgen Wolf, MD
University Hospital of Cologne
Köln, Germany



Faculty
Tina Cascone, MD, PhD
MD Anderson Cancer Center
Houston, Texas, United States



Faculty
Jose Luis Campo-Cañaverl de la Cruz, MD, PhD
Puerta de Hierro-Majadahonda
University Hospital
Madrid, Spain

13:00 – 13:10
(10 minutes)

Welcome and Introductions
Jürgen Wolf, MD

13:10 – 13:30
(20 minutes)

A Foundation for Survivorship With I-O and Potential New Approaches for Patients With ROS1+ NSCLC
Jürgen Wolf, MD

13:30 – 13:55
(25 minutes)

Multidisciplinary Approach to Managing the Expanding Options With I-O in Non-Metastatic NSCLC
Tina Cascone, MD, PhD; Jose Luis Campo-Cañaverl de la Cruz, MD, PhD

13:55 – 14:18
(23 minutes)

We Are NSCLC Clinicians: Ask Us Anything
All faculty

14:18 – 14:20
(2 minutes)

Closing Remarks
Jürgen Wolf, MD

This Industry-Sponsored Symposium Is a Medical Education Activity That Is Organized and Funded by the Medical Department of Bristol Myers Squibb.